• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Relievant Medsystems heads for Minnesota after $58m Series E

Relievant Medsystems heads for Minnesota after $58m Series E

June 27, 2018 By Brad Perriello

RelievantRelievant Medsystems said yesterday that it plans to move to Minnesota now that it’s closed on a $58 million Series E round.

Led by Endeavour Vision, joined by new backer RK Mellon and existing investors New Enterprise Assoc., Canaan Ventures, Morgenthaler and Emergent Ventures, the round is earmarked for U.S. commercialization of Relievant’s Intracept intraosseous nerve ablation system for treating chronic lower back pain.

Although it plans to maintain its R&D and operations facility in Sunnyvale, Calif., Relievant said it plans to move its HQ to Minneapolis.

The cash infusion is also slated for a second randomized trial of the Intracept device; one-year results from a prior study released in February showed a statistically significant difference between patients treated with Intracept and a sham treatment cohort.

“We are pleased to have the support and confidence of this highly respected group of investors,” president & CEO Kevin Hykes said in prepared remarks. “These new funds will facilitate the U.S. commercial launch of the Intracept procedure, providing a new, clinically-proven option to the more than five million indicated patients for whom today’s limited CLBP treatment options have proven ineffective.”

“Endeavour Vision is proud to partner with Relievant to support the launch of this important new therapy,” added Endeavour Vision senior investment director Alexander Schmitz, who joined Relievant’s board in connection with the financing. “The ability to intervene early in the CLBP treatment continuum with the Intracept procedure has the potential to significantly reduce pain and disability, decrease use of healthcare resources, and positively impact the opioid epidemic.”

Relievant raised a $36 million round back in October 2016.

Filed Under: Funding Roundup, Neuromodulation/Neurostimulation, Pain Management, Wall Street Beat Tagged With: Relievant Medsystems Inc.

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy